申请人:Pfizer Inc.
公开号:US05498610A1
公开(公告)日:1996-03-12
The present invention is directed to a method of blocking N-methyl-D-aspartic (NMDA) acid receptor sites in a mammal in need thereof with an effective NMDA blocking (neuroprotective and antiischemic) amount of 5-(1-hydroxy-2-piperidino)-propyl-2(1H,3H)-indolone analogs and the pharmaceutically acceptable salts thereof; methods of using these compounds in the treatment of stroke, head trauma, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised.
本发明涉及一种用有效的NMDA阻断(神经保护和抗缺血)量的5-(1-羟基-2-哌啶基)-丙基-2(1H,3H)-吲哚酮类似物及其药学上可接受的盐,用于阻断哺乳动物中N-甲基-D-天冬氨酸(NMDA)酸受体位点的方法;以及使用这些化合物治疗中风、头部创伤、脊髓创伤、创伤性脑损伤、多梗塞性痴呆、中枢神经系统退行性疾病,如阿尔茨海默病、老年阿尔茨海默型痴呆、亨廷顿病、帕金森病、癫痫、肌萎缩侧索硬化、疼痛、艾滋病痴呆、精神病症状、药物成瘾、偏头痛、低血糖、抗焦虑症状、尿失禁和由中枢神经系统手术、心脏开放手术或在心血管系统功能受损期间进行的任何程序引起的缺血事件的方法。